DNM2

Across TCGA pan-cancer cohorts, DNM2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DNM2 data layer compared with 21 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher DNM2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DNM2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SCLC, UCEC, and HNSC are the cancer types where DNM2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.082	0.708	<.001	36	view →
UCEC	OS	Median	All	0.974	0.864	.031	14	view →
HNSC	OS	Median	III,IV	0.001	0.675	<.001	12	view →
PRAD	DFS	Median	All	0.765	0.935	.003	6	view →
SKCM	DFS	Median	All	0.359	0.617	.028	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DNM2–SCLC (OS)

Open the SCLC breakdown →